Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat

Abstract

BACKGROUND We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. CASE PRESENTATION A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy. CONCLUSION This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.

DOI: 10.1186/s12890-016-0229-x

Extracted Key Phrases

Cite this paper

@inproceedings{Poch2016CaseRA, title={Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat}, author={David S. Poch}, booktitle={BMC pulmonary medicine}, year={2016} }